Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost
South Africa
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,
Created on
April 29, 2024
Last modified
April 29, 2024
Page views
24620
Download
2
Documentation in PDF
Metadata
DDI/XML
JSON
- Data files
- SHERPA_Safetydata
art_drug_3 (art_drug_3)
Data file: SHERPA_Safetydata
Overview
Valid:
44
Invalid:
0
Type:
Discrete
Width:
20
Range:
-
Format:
character
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| 3TC | 2 |
4.5%
|
|
| AZT | 1 |
2.3%
|
|
| Alluvi100/50 | 2 |
4.5%
|
|
| Alluvia | 4 |
9.1%
|
|
| Alluvia 2 tablets BD | 2 |
4.5%
|
|
| Aluvia | 1 |
2.3%
|
|
| DK | 1 |
2.3%
|
|
| DTG | 1 |
2.3%
|
|
| EFV | 1 |
2.3%
|
|
| Efavirenz | 3 |
6.8%
|
|
| Emitricitabine | 1 |
2.3%
|
|
| Emtricitabine | 2 |
4.5%
|
|
| LAMIVIDINE | 1 |
2.3%
|
|
| LOPINAVIR/RITONAVIR | 1 |
2.3%
|
|
| Lamivudine | 2 |
4.5%
|
|
| Lamuvudine | 1 |
2.3%
|
|
| N/A | 6 |
13.6%
|
|
| N/AN | 1 |
2.3%
|
|
| Norvir | 1 |
2.3%
|
|
| OTHER | 1 |
2.3%
|
|
| Ritonavir | 1 |
2.3%
|
|
| Truvada | 1 |
2.3%
|
|
| Truvada as PrEP | 1 |
2.3%
|
|
| Unknown | 1 |
2.3%
|
|
| dolutegravir | 1 |
2.3%
|
|
| efavirenz | 1 |
2.3%
|
|
| lamivudine | 2 |
4.5%
|
|
| unknown | 1 |
2.3%
|
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.